Robotic Vs. Traditional Verticalization in Patients with Severe Acquired Brain Injury: a Randomized Controlled Trial
Launched by ANNA ESTRANEO · Jun 19, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods to help patients with severe acquired brain injury (sABI) learn to stand up or get into an upright position. One method uses a robotic device that helps move the lower limbs, while the other is the traditional way of helping patients stand. The goal is to see which method is more effective for patients who are currently unable to stand on their own after their injury.
To be eligible for this study, patients need to have a stable diagnosis of a disorder of consciousness, meaning they may have some awareness but are not fully alert, and they should be between 28 days to 6 months post-injury. They also need to have consent provided by themselves or their primary caregiver. Participants can expect to be part of a larger group of patients and will receive either the robotic or traditional method to help them stand. This study aims to improve rehabilitation practices for patients with brain injuries, making it an important step in their recovery journey.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Stable clinical diagnosis of pDoC based on repeated Coma Recovery Scale -revised, CRS-R, or emerged from DoC (Level of Cognitive Functioning, LCF ≥4)
- • Time post-injury 28 days- 6 months ;
- • non-recovered upright station
- • Signed informed consent by the patient or by the patient's primary caregiver.
- Exclusion Criteria:
- • Severe medical conditions influencing clinical diagnosis and EEG activity (e.g., sub-continuous or abundant EEG epileptiform discharges) or hampering verticalization (e.g., severe hypotension or cardio-vascular instability) or lower limb mobilization (e.g., fractures, heterotopic ossifications).
About Anna Estraneo
Anna Estraneo is a dedicated clinical trial sponsor focused on advancing medical research and innovation. With a commitment to improving patient outcomes, the organization partners with leading healthcare professionals and institutions to design and conduct rigorous clinical trials. By prioritizing ethical standards and patient safety, Anna Estraneo strives to facilitate the development of groundbreaking therapies and medical solutions, ultimately contributing to the enhancement of healthcare practices. Through its collaborative approach and emphasis on scientific integrity, the sponsor aims to bridge the gap between research and practical application, fostering advancements that benefit both patients and the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pavia, , Italy
Sant'angelo Dei Lombardi, Avellino, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported